Tumor-Draining Lymph Nodes Contain Immunodominant Peptide-Specific T Cells which Demonstrate Efficacy in Murine Models of Adoptive Immunotherapy

@inproceedings{Choong2017TumorDrainingLN,
  title={Tumor-Draining Lymph Nodes Contain Immunodominant Peptide-Specific T Cells which Demonstrate Efficacy in Murine Models of Adoptive Immunotherapy},
  author={Kevin K. L. Choong and John B Ammori and Khaled Ziad Hamzeh and Hallie Graor and Julian Kyung-So Kim},
  year={2017}
}
Background: The purpose of this study was to determine whether tumor draining lymph nodes (TDLNs) contain the necessary components to process and present tumor-rejection antigens. The secondary objective was to determine whether short term ex vivo culture of TDLNs could generate peptide-reactive T cells with specific anti-tumor effector function in vivo . Methods: 4T1 and RENCA cancer cell lines were transfected with an expression plasmid containing HER2. These cell lines were then inoculated… CONTINUE READING

Similar Papers

Figures and Topics from this paper.

References

Publications referenced by this paper.
SHOWING 1-10 OF 33 REFERENCES

Phase II trial of autologous tumor vaccination, anti-CD3-activated vaccine-primed lymphocytes, and interleukin-2 in stage IV renal cell cancer

Chang, A.E
  • J Clin Oncol,
  • 2003
VIEW 5 EXCERPTS
HIGHLY INFLUENTIAL

A phase I trial of tumor lysate-pulsed dendritic cells in the treatment of advanced cancer

Chang, A.E
  • Clin Cancer Res,
  • 2002
VIEW 5 EXCERPTS
HIGHLY INFLUENTIAL

Expanded tumor-reactive CD4+ T-cell responses to human cancers induced by secondary anti-CD3/anti-CD28 activation.

  • Clinical cancer research : an official journal of the American Association for Cancer Research
  • 1999
VIEW 5 EXCERPTS
HIGHLY INFLUENTIAL

Clinical observations on adoptive immunotherapy with vaccine-primed T-lymphocytes secondarily sensitized to tumor in vitro

Chang, A.E
  • Cancer Res,
  • 1993
VIEW 5 EXCERPTS
HIGHLY INFLUENTIAL